A nanotechnology called the "Lab-on-Bead" process may hasten and simplify the search for new cancer drugs.
Developed by researchers at Wake Forest University, the process will screen millions of chemicals simultaneously using tiny plastic beads, so small that 1,000 of them can be placed on a single strand of human hair.
Liver Cancer - Animation
Liver is the largest organ inside the human body. It performs 500 different functions and processes 720 liters of blood per day. The important functions of the liver, the development of liver cancer and it's symptoms are presented in this interactive.
Advertisement
Each bead in the process contains a different chemical, which, if turns out to be successful in treating cancer, can be identified later.
A single batch of nanoscopic beads can easily match thousands of conventional, repetitive laboratory tests.
"This process allows the beads to do the work for you. By working at this scale, we will be able to screen more than a billion possible drug candidates per day as opposed to the current limit of hundreds of thousands per day," explained Jed Macosko, project director and assistant professor of physics at Wake Forest.
He further said that they were developing a new device that could automate the Lab-on-Bead process, and permit parallel processing to attain faster screening results.
The researchers are also working with biotechnologists at Harvard University in Boston and Universite Louis Pasteur in Strasbourg, France, which are providing the chemicals being screened for drug candidates.
Source: ANI
RAS/SK
"This process allows the beads to do the work for you. By working at this scale, we will be able to screen more than a billion possible drug candidates per day as opposed to the current limit of hundreds of thousands per day," explained Jed Macosko, project director and assistant professor of physics at Wake Forest.
Advertisement
He further said that they were developing a new device that could automate the Lab-on-Bead process, and permit parallel processing to attain faster screening results.
The researchers are also working with biotechnologists at Harvard University in Boston and Universite Louis Pasteur in Strasbourg, France, which are providing the chemicals being screened for drug candidates.
Source: ANI
RAS/SK
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.